Spots Global Cancer Trial Database for androgen receptor
Every month we try and update this database with for androgen receptor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Effect of Androgen Receptor Polymorphism on Endometrial Cancer | NCT05157373 | Androgen Recept... Endometrial Dis... | Endometrial sam... FSFI Scale | 18 Years - 90 Years | University of Nicosia | |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | NCT05241613 | Metastatic Cast... | AC176 | 18 Years - | Accutar Biotechnology Inc | |
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer | NCT04869943 | Metastatic Brea... | Enobosarm Exemestane | 18 Years - 100 Years | Veru Inc. | |
| Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer | NCT02910050 | Breast Cancer | Bicalutamide Aromatase Inhib... | 18 Years - 80 Years | Sun Yat-sen University | |
| Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | NCT04926181 | Small Cell Neur... Prostate Cancer Small Cell Carc... | Apalutamide Cetrelimab | 18 Years - | University of California, San Francisco | |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) | NCT03050866 | Circulating Tum... Metastatic Pros... | Cabazitaxel Antihistamine Corticosteroid H2 antagonist Antiemetic | 18 Years - | Erasmus Medical Center | |
| Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | NCT00878436 | Prostate Cancer Prostatic Neopl... | Panobinostat Bicalutamide | 18 Years - | NYU Langone Health | |
| A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer | NCT01337518 | Prostatic Neopl... | EZN-4176 | 18 Years - | Enzon Pharmaceuticals, Inc. | |
| Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | NCT00878436 | Prostate Cancer Prostatic Neopl... | Panobinostat Bicalutamide | 18 Years - | NYU Langone Health | |
| Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients | NCT02348281 | Breast Cancer | Bicalutamide | 18 Years - 70 Years | Fudan University | |
| pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer | NCT04090528 | Castration-resi... Metastatic Canc... Prostate Cancer | pTVG-HP pTVG-AR Pembrolizumab | 18 Years - | University of Wisconsin, Madison | |
| An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants | NCT02294461 | Progressive Met... | Enzalutamide Placebo | 18 Years - | Astellas Pharma Inc | |
| Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer | NCT03478904 | Prostate Cancer | Enzalutamide Li... Enzalutamide Ca... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer | NCT00918385 | Prostate Cancer | Nilutamide Dasatinib | 18 Years - | Duke University | |
| A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer | NCT02162836 | Prostatic Neopl... | JNJ-56021927 | 20 Years - | Janssen Pharmaceutical K.K. | |
| Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients | NCT02348281 | Breast Cancer | Bicalutamide | 18 Years - 70 Years | Fudan University | |
| Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer | NCT03478904 | Prostate Cancer | Enzalutamide Li... Enzalutamide Ca... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer | NCT04869943 | Metastatic Brea... | Enobosarm Exemestane | 18 Years - 100 Years | Veru Inc. | |
| Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) | NCT03050866 | Circulating Tum... Metastatic Pros... | Cabazitaxel Antihistamine Corticosteroid H2 antagonist Antiemetic | 18 Years - | Erasmus Medical Center | |
| Androgen Deprivation Therapy in Advanced Salivary Gland Cancer | NCT01969578 | Salivary Gland ... | bicalutamide + ... Cisplatin + Dox... Carboplatin + P... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants | NCT02294461 | Progressive Met... | Enzalutamide Placebo | 18 Years - | Astellas Pharma Inc | |
| pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer | NCT04090528 | Castration-resi... Metastatic Canc... Prostate Cancer | pTVG-HP pTVG-AR Pembrolizumab | 18 Years - | University of Wisconsin, Madison | |
| An Open Label Prostate Cancer Study in Japanese Patients | NCT01351688 | Prostate Cancer | AZD3514 | 20 Years - | AstraZeneca | |
| Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients | NCT02348281 | Breast Cancer | Bicalutamide | 18 Years - 70 Years | Fudan University | |
| Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer | NCT02910050 | Breast Cancer | Bicalutamide Aromatase Inhib... | 18 Years - 80 Years | Sun Yat-sen University | |
| Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | NCT04926181 | Small Cell Neur... Prostate Cancer Small Cell Carc... | Apalutamide Cetrelimab | 18 Years - | University of California, San Francisco | |
| Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC | NCT03437941 | Metastatic Cast... | CORT125281 Enzalutamide (X... Placebo | 18 Years - | Corcept Therapeutics | |
| A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer | NCT02162836 | Prostatic Neopl... | JNJ-56021927 | 20 Years - | Janssen Pharmaceutical K.K. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
